Mattia Bugatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mattia Bugatti has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Fabio Facchetti
Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy
29 shared publications - Silvia Lonardi
Pathology Section, Department of Molecular and Translational Medicine, University of Brescia and Pathology Unit, ASST Spedali Civili di Brescia, Brescia, Italy
29 shared publications - Adrian Andronache
Experimental Therapeutics Program, IFOM ETS - The AIRC Institute of Molecular Oncology Milan, Italy
27 shared publications - Alessandra Tucci
Hematology Division, ERN/EuroloodNet, ASST Spedali Civili di Brescia, Brescia, Italy
27 shared publications - Andrés José Maria Ferreri
Strategic Program on Lymphomas IRCCS San Raffaele Scientific Institute, Milano and Vita‐Salute San Raffaele University Milan Italy
27 shared publications - Anojan Sivacegaram
Genetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy
27 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7147
Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma
Therapeutic resistance remains a critical obstacle in rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma. Increasing evidence implicates redox adaptation in tumor survival and treatment failure. Here, we investigated the functional role and clinical relevance of catalase, a primary hydrogen peroxide-detoxifying enzyme, in modulating RMS therapeutic response. Integrated transcriptomic analyses revealed that while catalase is overall downregulated in RMS compared to healthy skeletal muscle, elevated expression strongly correlates with high-risk, metastatic disease and poor overall survival. In human RMS cell lines, catalase was detectable, and its pharmacological inhibition using 3-amino-1,2,4-triazole (3-ATA) promoted reactive oxygen species (ROS) accumulation, sensitizing cells to standard chemotherapeutics. Notably, robust catalase upregulation was observed in RMS cell models characterized by intrinsic and acquired radioresistance, with strong immunoreactivity validated on cell-block sections. Immunohistochemical validation across patient specimens revealed generally weak catalase expression in RMS tumors, whereas strong reactivity was observed in a secondary embryonal RMS (ERMS) arisen following chemoradiotherapy for nasopharyngeal carcinoma. Functionally, targeting catalase with 3-ATA restored both radio- and chemosensitivity in radioresistant RMS lines. Furthermore, co-targeting catalase and Akt using sub-toxic doses of 3-ATA and MK-2206 cooperatively enhanced oxidative stress-mediated cytotoxicity in resistant cells. Together, these findings identify catalase as a pivotal driver of adaptive radioresistance and establish dual catalase/Akt targeting as a promising pro-oxidant strategy to overcome radiotherapy resistance in RMS.
- 10 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7147
Open AccessCatalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma
Therapeutic resistance remains a critical obstacle in rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma. Increasing evidence implicates redox adaptation in tumor survival and treatment failure. Here, we investigated the functional role and clinical relevance of catalase, a primary hydrogen peroxide-detoxifying enzyme, in modulating RMS therapeutic response. Integrated transcriptomic analyses revealed that while catalase is overall downregulated in RMS compared to healthy skeletal muscle, elevated expression strongly correlates with high-risk, metastatic disease and poor overall survival. In human RMS cell lines, catalase was detectable, and its pharmacological inhibition using 3-amino-1,2,4-triazole (3-ATA) promoted reactive oxygen species (ROS) accumulation, sensitizing cells to standard chemotherapeutics. Notably, robust catalase upregulation was observed in RMS cell models characterized by intrinsic and acquired radioresistance, with strong immunoreactivity validated on cell-block sections. Immunohistochemical validation across patient specimens revealed generally weak catalase expression in RMS tumors, whereas strong reactivity was observed in a secondary embryonal RMS (ERMS) arisen following chemoradiotherapy for nasopharyngeal carcinoma. Functionally, targeting catalase with 3-ATA restored both radio- and chemosensitivity in radioresistant RMS lines. Furthermore, co-targeting catalase and Akt using sub-toxic doses of 3-ATA and MK-2206 cooperatively enhanced oxidative stress-mediated cytotoxicity in resistant cells. Together, these findings identify catalase as a pivotal driver of adaptive radioresistance and establish dual catalase/Akt targeting as a promising pro-oxidant strategy to overcome radiotherapy resistance in RMS.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure S6 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S6 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
DLBCL cases included in the study.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
DLBCL cases included in the study.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Supplementary Table S7 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Bulk and spatial gene expression data of MYC and BCL2 dual expressor DLBCL and HGBCL-DH-BCL2 (-BCL6).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Bulk and spatial gene expression data of MYC and BCL2 dual expressor DLBCL and HGBCL-DH-BCL2 (-BCL6).
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Non synonymus SNVs, IGHV gene rearrangements, AID expression status and N-glycosylation motifs in IGHV domains of HGBCL-DH-BCL2(-BCL6).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Non synonymus SNVs, IGHV gene rearrangements, AID expression status and N-glycosylation motifs in IGHV domains of HGBCL-DH-BCL2(-BCL6).